Logo

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Share this
Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Shots:

  • The P-III (DISCOVER-1 & 2) & (COSMOS) studies evaluate Tremfya in patients with active PsA. The results showed that patients achieved consistent, long-term efficacy @2yrs. across PsA including joint, skin, enthesitis, dactylitis, spinal pain & disease severity EPs. In (DISCOVER-2) study, 40% achieved MDA, 59% DAPSA score of ≤14, & 24% DAPSA ≤4 @100wk.
  • The (COSMOS) study showed complete resolution of dactylitis in ≥80% who continued to receive Tremfya @48wk. The safety profile was consistent with that observed in PsO
  • The additional analyses showed sustained improvements in measures of HRQoL including fatigue, pain, work productivity & low rates of radiographic progression @2yrs. in biologic-naïve active PsA patients

Ref: Janssen  | Image: Janssen 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions